NPY1R and lip and oral cavity carcinoma: When the NPY1R andNPY2R promoters were methylated in patients with oral cancers, the ratios were 2.39 (95% CI, 1.06–5.37; P = 0.036) and 2.93 (95% CI, 1.25–6.88; P = 0.014), respectively, and the hazard rate was 3.9 times higher (95% CI, 1.52–9.99; P = 0.005) (Figure 3).